Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1997-03-18
2000-04-25
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514602, 514603, A61K 3118
Patent
active
060544872
ABSTRACT:
Method for modulating responsiveness to corticosteroids in a subject are provided. In the method of the invention, an agent which antagonizes a factor that regulates production of IFN-.gamma. in the subject is administered to the subject in combination with a corticosteroid such that responsiveness of the subject to the corticosteroid is modulated as compared to when a corticosteroid alone is administered to the subject. In one embodiment, the agent is an interferon-.gamma. inducing factor (IGIF) antagonist. In another embodiment, the agent is an interleukin-12 (IL-12) antagonist. In a preferred embodiment, the agent is an inhibitor of a caspase family protease, preferably an ICE inhibitor. In another preferred embodiment, the agent is an anti-IL-12 monoclonal antibody. Other preferred agents include phosphodiesterase IV inhibitors and beta-2 agonists. The methods of the invention can be used in the treatment of a variety of inflammatory and immunological diseases and disorders. Pharmaceutical compositions comprising an agent which antagonizes a factor that regulates production of IFN-.gamma. in a subject, a corticosteroid and a pharmaceutically acceptable carrier are also provided. A preferred composition comprises an ICE inhibitor, a corticosteroid and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 3320125 (1967-05-01), Grim
patent: 5411985 (1995-05-01), Bills et al.
patent: 5416013 (1995-05-01), Black et al.
patent: 5430128 (1995-07-01), Chapman et al.
patent: 5434248 (1995-07-01), Chapman et al.
patent: 5536657 (1996-07-01), Chua et al.
patent: 5565430 (1996-10-01), Dolle et al.
patent: 5656627 (1997-08-01), Bemis et al.
Deitzman et al., Acta Chir. Belg., 72(4), 308-30 (Abstract), 1973.
Almqvist et al., Acta Chir. Scand., Suppl., 526, 120-3 (Abstract), 1985.
Antin, J.H. et al., "Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease" Blood 84(4):1342-1348 (1994).
Banner, K.H. et al., "The effect of selective phosphodiesterase 3 and 4 isoenzyme inhibitors and established anti-asthma drugs on inflammatory cell activation" British Journal of Pharmacology 119:1255-1261 (1996).
Baxter, J.D., "The effects of glucocorticoid therapy" Hospital Practice 27(9):111-18, 123-134 (1992).
Bazan, J.F. et al., "A newly defined interleukin-1?" Nature 379:591 (1996).
Cerretti, D. P. et al., "Molecular cloning of the interleukin-1.beta. converting enzyme" Science 256:97-100 (1992).
Chizzonite, R. et al., "IL-12: monoclonal antibodies specific for the 40-kDa subunit block receptor binding and biologic activity on activated human lymphoblasts" The Journal of Immunology 147:1548-1556 (1991).
Cohan, V.L. et al., "In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633" The Journal of Pharmacology and Experimental Therapeutics 278:1356-1361 (1996).
Dolle, R.E. et al., "P.sub.1 aspartate-based peptide .alpha.-((2,6-Dichlorobenzoyl)oxy)methyl keytones as potent time-dependent inhibitors of interleukin-1.beta.-converting enzyme" J. Med. Chem. 37:563-564 (1994).
Gately, M.K, et al., "Interleukin-12 antagonist activity of mouse interleukin-12 p40 homodimer in vitro and in vivo" Annals New York Academy of Sciences 795:1-12 (1996).
Geiger, T. et al., "Inteferon-.gamma. overcomes the glucocorticoid-mediated and the interleukin-4 mediated inhibition of interleukin-1.beta. synthesis in human monocytes" Lymphokine and Cytokine Research 12(5):271-278 (1993).
Gillessen, S. et al., "Mouse interleukin-12 (IL-12) p40 homodimer: a potent IL-12 antagonist" Eur. J. Immunol. 25:200-206 (1995).
Gu, Y. et al., "Activation of interferon-.gamma. inducing factor medicated by interleukin 1.beta. converting enzyme" Science 275:206-209 (1997).
Kam, J.C. et al, "Combination IL-2 and IL-4 reduces glucocorticoid receptor-binding affinity and T cell response to glucocorticoids" The Journal of Immunology 151:3460-3466 (1993).
Kaplan, M.H. et al., "Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice" Nature 382:174-177 (1996).
Kimberly, R.P., "Glucocorticoid therapy for rheumatic diseases" Current Opinion in Rheumatology 4:325-331 (1992).
Kimberly, R.P., "Mechanisms of action, dosage schedules, and side effects of steroid therapy" Current Opinion in Rheumatology 3:373-379 (1991).
Kuida, K. et al., "Altered cytokine export and apoptosis in mice deficient in interleukin-1.beta. converting enzyme"Science 267:2000-2003 (1995).
Leonard, J.P. et al., "Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12" J. Exp. Med. 181:381-386 (1995).
Li, P. et al., "Mice deficient in IL-1.beta.-converting enzyme are defective in production of mature IL-1 .beta. and resistant to endotoxic shock" Cell 80:401-411 (1995).
Ling, P. et al., "Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity" The Journal of Immunology 154:116-127 (1995).
Luedke, C.E. et al., "Interferon-.gamma. overcomes glucocorticoid suppression of cachectin/tumor necrosis factor biosynthesis by murine macrophages" J Clin. Invest. 86:1234-1240 (1990).
Neurath, M.N. et al., "Antibodies to interleukin 12 abrogate established experimental colitis in mice" The Journal of Experimental Medicine 182:1281-1290 (1995).
Okamura, H. et al., "Cloning of a new cytokine that induces IFN-.gamma. production by T cells" Nature 378:88-91 (1995).
Presky, D.H. et al., "Immunoregulation by interleukin-12: IL 12 receptors and receptor antagonists" Res. Immunol. 146:439-445 (1995).
Schoenhaut, D.S. et al., "Cloning and expression of murine IL-12" The Journal of Immunology 148:3433-3440 (1992).
Sekut, L. et al., "Anti-inflammatory activity of phosphosiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation" Clin. Exp. Immunol. 100:126-132 (1995).
Sekut, L. et al, "Anti-inflammatory activity of salmeterol: down-regulation of cytokine production" Clin. Exp. Immunol. 99:461-466 (1995).
Severn, A. et al., "Regulation of tumor necrosis factor production by adrenaline and .beta.-adrenergic agonists" The Journal of Immunology 148:3441-3445 (1992).
Sjolin, J., "High-dose corticosteroid therapy in human septic shock: has the jury reached a correct verdict?" Circulatory Shock 35:139-151 (1991).
Thornberry, N.A. et al., "A novel heterodimeric cysteine protease is required for interleukin-1.beta. processing in monocytes" Nature 356:768-774 (1992).
Thierfelder, W.E. et al., "Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells" Nature 382:171-174 (1996).
Truhan, A.P. et al., "Corticosteroids: a review with emphasis on complications of prolonged systemic therapy" Annals of Allergy 62:375-391 (1989).
Ushio, S. et al., "Cloning of the cDNA for human IFN-.gamma.-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein" The Journal of Immunology 156:4274-4279 (1996).
van der Pouw Kraan, T.C.T.M. et al., "Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production" J. Exp. Med. 181:775-779 (1995).
van Wauwe, J. et al., "Cytokine production by phytohemagglutinin-stimulated human blood cells: effects of corticosteroids, T cell immunosuppressants and phosphodiestrase IV inhibitors" Inflamm. Res. 44:400-405 (1995).
Weisman, M.H. et al., "Corticosteroids in the treatment of rheumatologic diseases" Current Opinion in Rheumatology 7:183-190 (1995).
Banerjee Subhashis
Carter Adam
Ghayur Tariq
Sekut Les
Tracey Daniel E.
BASF - Aktiengesellschaft
Jarvis William R. A.
LandOfFree
Methods and compositions for modulating responsiveness to cortic does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for modulating responsiveness to cortic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for modulating responsiveness to cortic will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-993741